Patti, Giuseppe
Pecen, Ladislav
Casalnuovo, Giuseppina
Manu, Marius Constantin
Kirchhof, Paulus
De Caterina, Raffaele
Funding for this research was provided by:
Università degli Studi del Piemonte Orientale Amedeo Avogrado
Article History
Received: 2 June 2022
Accepted: 1 August 2022
First Online: 17 August 2022
Declarations
:
: G.P.: speaker or consultant fee from Astra Zeneca, Boehringer Ingelheim, Bayer, BMS, Pfizer, Daiichi Sankyo, Sanofi, Amgen, Novartis, Terumo, Abbott, Medtronic, PIAM, Chiesi, Menarini, Malesci, Servier. Grants from Astra Zeneca, Bayer, Abbott, Boston Scientific. L.P.: none. G.C.: employed by Daiichi Sankyo Italia S.p.A., Rome, Italy. M.C.M.: employed by Daiichi Sankyo Europe GmbH, Munich, Germany. P.K. was partially supported by European Union BigData@Heart (grant agreement EU IMI 116074), AFFECT-AF (grant agreement 847770), and MAESTRIA (grant agreement 965286), British Heart Foundation (PG/17/30/32961; PG/20/22/35093; AA/18/2/34218), German Centre for Cardiovascular Research supported by the German Ministry of Education and Research (DZHK), and Leducq Foundation. PK receives research support for basic, translational, and clinical research projects from European Union, British Heart Foundation, Leducq Foundation, Medical Research Council (UK), and German Centre for Cardiovascular Research, from several drug and device companies active in atrial fibrillation, and has received honoraria from several such companies in the past, but not in the last 3 years. PK is listed as inventor on two patents held by University of Birmingham (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). R.D.C.: grants, speaker or consultant fee from Boehringer Ingelheim, Bayer, BMS/Pfizer, Janssen, Daiichi Sankyo, Novartis, AstraZeneca, Milestone, Lilly, Roche, Menarini, Guidotti and Nominating Committee from European Society of Cardiology.